- Home
- CGEN vs SKIL Comparison
CGEN vs SKIL Comparison
Compare CGEN & SKIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- SKIL
- Stock Information
- Founded
- CGEN 1993
- SKIL 1998
- Country
- CGEN Israel
- SKIL United States
- Employees
- CGEN N/A
- SKIL N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- SKIL Computer Software: Prepackaged Software
- Sector
- CGEN Health Care
- SKIL Technology
- Exchange
- CGEN Nasdaq
- SKIL Nasdaq
- Market Cap
- CGEN 135.6M
- SKIL 142.2M
- IPO Year
- CGEN 2000
- SKIL N/A
- Fundamental
- Price
- CGEN $1.47
- SKIL $22.07
- Analyst Decision
- CGEN Strong Buy
- SKIL Strong Buy
- Analyst Count
- CGEN 1
- SKIL 1
- Target Price
- CGEN $4.00
- SKIL $50.00
- AVG Volume (30 Days)
- CGEN 268.4K
- SKIL 37.4K
- Earning Date
- CGEN 05-19-2025
- SKIL 04-14-2025
- Dividend Yield
- CGEN N/A
- SKIL N/A
- EPS Growth
- CGEN N/A
- SKIL N/A
- EPS
- CGEN N/A
- SKIL N/A
- Revenue
- CGEN $27,864,000.00
- SKIL $530,994,000.00
- Revenue This Year
- CGEN $11.81
- SKIL $4.49
- Revenue Next Year
- CGEN $28.37
- SKIL $6.77
- P/E Ratio
- CGEN N/A
- SKIL N/A
- Revenue Growth
- CGEN N/A
- SKIL N/A
- 52 Week Low
- CGEN $1.13
- SKIL $5.09
- 52 Week High
- CGEN $2.66
- SKIL $34.43
- Technical
- Relative Strength Index (RSI)
- CGEN 49.50
- SKIL 56.77
- Support Level
- CGEN $1.13
- SKIL $16.71
- Resistance Level
- CGEN $1.35
- SKIL $22.31
- Average True Range (ATR)
- CGEN 0.11
- SKIL 1.75
- MACD
- CGEN 0.03
- SKIL 0.67
- Stochastic Oscillator
- CGEN 85.00
- SKIL 97.00
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About SKIL Skillsoft Corp.
Skillsoft Corp is a leader in corporate digital learning. The company's segment includes Content & Platform and Instructor-Led Training. The Content & Platform business engages in the sale, marketing and delivery of its content learning solutions, in areas such as Leadership and Business, Technology and Developer and Compliance. The Instructor-Led Training business offers training solutions covering information technology and business skills for corporations and their employees. The majority of revenue is from the Content & Platform segment.